GIA
MRNA icon

Granite Investment Advisors’s Moderna MRNA Stock Holding History

Granite Investment Advisors’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$393K Buy
+1,021
New +$377K 0.06% 138

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return

Granite Investment Advisors's MRNA Position: Q3 2021 in Review

Granite Investment Advisors opened a new position in Moderna (MRNA) in Q3 2021: 1,021 shares worth $393K. The stake represents 0.06% of the portfolio and ranks #138 among its holdings.

1,140 funds tracked by Wall St. Rank hold MRNA as of Q3 2021.

  • Granite Investment Advisors held 1,021 shares of Moderna worth $393K as of Q3 2021.
  • Moderna was a new Granite Investment Advisors position in Q3 2021.
  • Moderna made up 0.06% of Granite Investment Advisors's portfolio in Q3 2021, its #138 holding.
  • 1,140 funds tracked by Wall St. Rank held Moderna as of Q3 2021.

Based on Granite Investment Advisors's 13F filing for Q3 2021, filed 8 Nov 2021.